ライフサイエンスコーパス: eye disease

1 approach in the treatment of age-related dry eye disease.

2 nts, treatment of atopic dermatitis, and dry eye disease.

3 d summarizes the role of inflammation in dry eye disease.

4 an be useful in understanding vessel-related eye disease.

5 effectiveness in future studies of diabetic eye disease.

6 outcome measures for moderate to severe dry eye disease.

7 , where an anti-VEGF agent was used to treat eye disease.

8 l for assessing novel interventions to treat eye disease.

9 col/propylene glycol in the treatment of dry eye disease.

10 tear secretion and prevent experimental dry eye disease.

11 ty in the evaluation and grading of diabetic eye disease.

12 abnormal Bruch Membrane thickness, a sign of eye disease.

13 ing, or differing demographics of those with eye disease.

14 tivation and initiation of immune-driven dry eye disease.

15 cifically regulated during immune-driven dry eye disease.

16 tional supplements for primary prevention of eye disease.

17 luding cancers, atherosclerosis and blinding eye disease.

18 uringly and drive pathogenesis of a blinding eye disease.

19 sic and clinical research of human inherited eye disease.

20 eening test results and visually significant eye disease.

21 gists in the management and treatment of dry eye disease.

22 rive the chronic and relapsing course of dry eye disease.

23 formation that remained depressed during dry eye disease.

24 opment of regenerative medical approaches to eye disease.

25 of the pathophysiological mechanisms of dry eye disease.

26 al abnormalities, including microcephaly and eye disease.

27 ye involvement in patients with mild thyroid eye disease.

28 , leading to a dysbiosis and immune-mediated eye disease.

29 ion, thus contributing to the development of eye disease.

30 ongitudinal population-based study of common eye disease.

31 er and multitarget approaches in neovascular eye disease.

32 t all (92.8%) were clinically diagnosed with eye disease.

33 ability, and disease phenotypes in inherited eye disease.

34 is lack of data on population prevalence of eye disease.

35 cell transfer did not alter the severity of eye disease.

36 d has potential as a novel treatment for dry eye disease.

37 echanism that implicates vascular biology in eye disease.

38 against desmosomal cadherins, often have dry eye disease.

39 getables, have beneficial effects in several eye diseases.

40 orm) and to mechanisms contributing to human eye diseases.

41 delivered 12 may be efficacious in human dry eye diseases.

42 athology images, and external photographs of eye diseases.

43 ngoing systemic severe pathology, asthma and eye diseases.

44 d their enzymatic metabolites in neovascular eye diseases.

45 a novel etiologic discovery for these common eye diseases.

46 egulating pathological neovascularization in eye diseases.

47 rrent uveitis, as well as other inflammatory eye diseases.

48 h human orthologs previously associated with eye diseases.

49 approach for allergic conjunctivitis and dry eye diseases.

50 and autoimmune diseases, lung diseases, and eye diseases.

51 and is reported to play pathogenic roles in eye diseases.

52 nce for changing clinical practice of common eye diseases.

53 ye, including in the pathophysiology of some eye diseases.

54 FTF examination for the detection of common eye diseases.

55 pression of GRIK5 with comorbid vascular and eye diseases.

56 assessed by ophthalmologist for presence of eye diseases.

57 plicated reduced GRIK5 expression in diverse eye diseases.

58 The mean ADC of lacrimal glands in thyroid eye disease (1.73 x 10(-3) mm(2)/s) was significantly hi

59 80 study participants had referable diabetic eye disease, 13.3% had vision-threatening disease, and 2

60 a common treatment strategy for neovascular eye disease, a major cause of vision loss in diabetic re

61 atients and those with aqueous deficient dry eye disease (ADDE).

62 tinopathy (PDR) in 31% and advanced diabetic eye disease (ADED) in 3% (n = 100).

63 s was not the case in a T-dependent allergic eye disease (AED) model, suggesting that this inflammato

64 romising visual acuity, is a hallmark of dry eye disease affecting 7 to 10% of individuals worldwide.

65 n trials and reviews of the 4 most prevalent eye diseases (age-related macular degeneration [AMD], ca

66 ides epidemiologic data on the prevalence of eye diseases among adult population in low-income urban

67 ed prevalence and associated risk factors of eye diseases among slum dwellers of Dhaka city.

68 Of identified patients, 38% had eye disease and 12% presented with other serious manifes

69 emales, with mean age 36 years) with thyroid eye disease and 20 age- and sex-matched volunteers.

70 onality in 757 patients (1514 eyes) with dry eye disease and 29 healthy controls (58 eyes).

71 ologous serum-based eye drops for severe dry eye disease and 4 studies of persistent epithelial defec

72 y congenital glaucoma (PCG) is a devastating eye disease and an important cause of childhood blindnes

73 Trachoma is a neglected eye disease and an important cause of preventable cornea

74 The adjusted odds ratio for dry eye disease and anxiety was 2.8 (95% confidence interval

75 ritical to early detection and prevention of eye disease and associated morbidity and mortality; howe

76 nesis-dependent diseases, including blinding eye disease and cancer.

77 For dry eye disease and depression, the odds ratio was 2.9 (95%

78 Separate odds ratios were calculated for dry eye disease and each of anxiety and depression.

79 stically significant association between dry eye disease and each of depression and anxiety.

80 idosis, somatic mutations in LCAT cause fish eye disease and familial LCAT deficiency.

81 ) T-cell subsets play a role in the blinding eye disease and in controlling virus replication.

82 utic target for the management of severe dry eye disease and ocular inflammation in pSS patients.

83 , dopamine and melatonin), may contribute to eye disease and pathology.

84 odds ratios were also calculated between dry eye disease and rheumatoid arthritis, a systemic disease

85 LASIK, further reducing the incidence of dry eye disease and subsequent degradation in quality of lif

86 oteins represent a potential therapy for dry eye disease and the strategy of ELP-mediated phase separ

87 can be further developed as a model for dry eye disease and therapeutic evaluation.

88 er that can be used for diagnosis of thyroid eye disease and to predict the active form of the diseas

89 HR ligands as future therapeutic options for eye diseases and possibly also for other scarring condit

90 rt for eye health research, and awareness of eye diseases and risk factors.

91 Implications for RPE-related eye diseases and the acne drug isotretinoin (a retinoid

92 Many Americans were unaware of important eye diseases and their behavioral or familial risk facto

93 es reported improved symptoms for severe dry eye disease, and all noted improvement in at least 1 cli

94 eases like corneal transplant rejection, dry eye disease, and allergy.

95 tion of memory Th17 cells to age-related dry eye disease, and evaluated memory Th17 cell depletion wi

96 Millions of Americans suffer from dry eye disease, and there are few effective therapies capab

97 also involved in the pathophysiology of dry eye disease, and TRPM8 activation has antiallodynic and

98 The aging population is at risk of common eye diseases, and routine eye examinations are recommend

99 ve and specific to AD in patients with other eye diseases, and validating potential biomarkers in pop

100 d complications after surgery, including dry eye disease, anterior or epithelial basement membrane dy

101 d according to ICD-9 diagnosis codes for dry eye disease, anxiety, and depression.

102 rs [AOR = 3.77; (1.05-13.5)]) and history of eye disease [AOR = 2.47; (1.09-5.62)] were associated wi

103 12 years [AOR = 4.4;(1.4-13.5)]), history of eye disease [AOR = 5.5;(2.3-13.0)] were associated with

104 ract, glaucoma, diabetic retinopathy and dry eye disease are common with high prevalence in Jordan.

105 Globally, eye diseases are considered as one of the major contribu

106 of eye disease was 60 months and duration of eye disease at baseline 145 months.

107 t age over 80 years, its contribution to the eye disease burden is expected to be remarkably high.

108 l demographics impact projections for future eye disease burden, causing state-level projections to v

109 cated in the pathogenesis and progression of eye diseases, but it remains unclear whether activation

110 a promising tool in the diagnosis of various eye diseases, but the available diagnostic evidence has

111 d as none, moderate, or severe VI) and major eye diseases (cataract, uncorrected refractive error, gl

112 C-HA/PTX3 is a novel approach to prevent dry eye disease caused by cGVHD and allow us to test its saf

113 major risk factor for glaucoma, a prevalent eye disease characterized by death of retinal ganglion c

114 Butterfly-shaped pigment dystrophy is an eye disease characterized by lesions in the macula that

115 ed within the 6-year follow-up of the Nakuru Eye Disease Cohort in central Kenya and included 300 adu

116 ry 7, 2013, to March 12, 2014) of the Nakuru Eye Disease Cohort in Kenya, 1460 adults (2920 eyes) 55

117 m the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study.

118 ithm in detecting sight-threatening diabetic eye disease compared with the reading center interpretat

119 udinal population-based study of age-related eye diseases conducted in the city and township of Beave

120 Dry eye disease (DED) affects millions of people worldwide.

121 estimates of the prevalence of diagnosed dry eye disease (DED) and associated demographics among US a

122 severity of ocular pain in patients with dry eye disease (DED) and evaluate factors associated with p

123 to compare patient-reported symptoms of dry eye disease (DED) as assessed by the Ocular Surface Dise

124 characteristics, including age, sex, and dry eye disease (DED) diagnostic parameters were collected.

125 Dry eye disease (DED) is a common ocular disorder affecting

126 Dry eye disease (DED) is a highly prevalent, ocular disorder

127 Dry Eye Disease (DED) is a multifactorial disease of the int

128 Dry eye disease (DED) is a prevalent complication of diabete

129 Dry eye disease (DED) is multifactorial, affecting 5-34 % of

130 Dry eye disease (DED) represents a heterogeneous group of co

131 SP was described in the pathogenesis of dry eye disease (DED) through its role in the maturation of

132 ssociation between serum metabolites and dry eye disease (DED) using a hypothesis-free metabolomics a

133 itiate a 5-year natural history study of dry eye disease (DED) using objectively assessed and patient

134 glaucoma, diabetic retinopathy (DR) and dry eye disease (DED) was assessed.

135 Diagnostic tests for dry eye disease (DED), including ocular surface disease inde

136 iscordance between symptoms and signs in dry eye disease (DED).

137 densities in the cornea were reduced in dry eye disease (DED).

138 ating the ocular surface autoimmunity in dry eye disease (DED).

139 riacylglyceride (fish oil), for treating dry eye disease (DED).

140 nist developed to reduce inflammation in dry eye disease (DED).

141 resents the primary cause of evaporative dry eye disease (DED).

142 ll-mediated inflammation associated with dry eye disease (DED).

143 inations in the key and high burden areas of eye disease, dementia and Parkinson's disease, culminati

144 classifiers representing different levels of eye diseases derived from a predefined hierarchical eye

145 ntion designed to improve glaucoma and other eye disease detection and follow-up care in high-risk po

146 r surface inflammation and may influence dry eye disease development and progression.

147 Ocular syphilis is an inflammatory eye disease due to Treponema pallidum infection.

148 e on the ocular surface of patients with dry eye disease during 60 days of intervention.

149 (MGD) is the major cause of evaporative dry eye disease (EDED) and dysfunction is widely thought to

150 amine whether HC-HA/PTX3 could attenuate dry eye disease elicited by cGVHD.

151 as a model of population-based screening for eye disease, FDT perimetry lacks both sensitivity and sp

152 ion to learn the fine-grained variability of eye diseases features.

153 pecialized in vitro model of evaporative dry-eye disease for high-content drug screening.

154 al gland used for differentiation of thyroid eye disease from volunteers was 1.62 x 10(-3) mm(2)/s wi

155 The oculome design covers 429 known eye disease genes; these are subdivided into 5 overlappi

156 linked to a heritable form of the prevalent eye disease, glaucoma, and 10 years ago, my lab set out

157 Next, we proposed a multi-level eye disease-guided loss function to learn the fine-grain

158 ces in understanding the pathogenesis of dry eye disease has revealed that inflammation is a core dri

159 pathogenesis of diverse cancers and blinding eye diseases has also become evident.

160 ibutes to the polygenic liability to develop eye diseases have helped to illuminate a mechanism that

161 ion and the pathophysiology of many blinding eye diseases, here we investigated whether the absence o

162 S, MM, WM and AL amyloidosis with subsequent eye diseases identified from the Swedish patient registe

163 eutic potential in treating HSV-1-associated eye disease.IMPORTANCE Glycoprotein K (gK) is an essenti

164 al, we assigned patients with active thyroid eye disease in a 1:1 ratio to receive intravenous infusi

165 ccurate and efficient means of screening for eye disease in an American Indian/Alaskan Native populat

166 with the development or worsening of thyroid eye disease in approximately 15% to 20% of patients.

167 eased CD8(+) T cells, leading to exacerbated eye disease in HSV-1-infected mice.IMPORTANCE HSV-1 ocul

168 the host immune response and, thus, reduces eye disease in ocularly infected mice.

169 ay be a useful tool to control HSV-1-induced eye disease in patients with herpes stromal keratitis (H

170 Inflammation was induced to mimic dry eye disease in the coculture model system.

171 s of clinical trial sites exist for diabetic eye disease in the United States.

172 high incidence of cataract formation and dry eye disease in this population, this study proposes thes

173 network of epidemiological studies of common eye diseases in adults across Europe.

174 sk for the development of common age-related eye diseases in older age.

175 (RP) is a genetically heterogenous group of eye diseases in which initial degeneration of rods trigg

176 Ds), visual acuity (VA) change, and diabetic eye disease incidence and progression.

177 Two insults often underlie a variety of eye diseases including glaucoma, optic atrophy, and reti

178 arrier (BRB) dysfunction in several blinding eye diseases, including diabetic retinopathy.

179 Neovascular eye diseases, including retinopathy of prematurity, diab

180 he prevalence as well as the severity of dry eye disease increase with age.

181 tralizing antibodies protect mice from HSV-1 eye disease, indicating the critical role of HVEM in HSV

182 In the context of a blinding eye disease, indirect activation of PDGFRalpha results i

183 are associated with heart-rate disturbance, eye disease, intellectual disability, gastric problems,

184 Thyroid eye disease is a debilitating, disfiguring, and potentia

185 Dry eye disease is a major public health problem that affect

186 nfection in the eye.IMPORTANCE HSV-1-induced eye disease is a major public health problem.

187 Eye disease is associated closely with immune responses

188 In experimental models, dry eye disease is associated with T helper cell 17-mediated

189 The prevalence of dry eye disease is high worldwide and poses a great burden o

190 In this study, we show that eye disease is independent of the level of HSV-1 replica

191 of the TNF superfamily, on HSV-1 latency and eye disease is not known.

192 Dry eye disease is the prominent ocular sequel of cGVHD and

193 Eye disease is the result of a prolonged immune response

194 The burden of untreated eye disease is very high among the Rohingya, particularl

195 mental health may be important correlates of eye disease knowledge and eye health information exposur

196 arch can be impaired in patients with common eye diseases like glaucoma and age-related macular degen

197 ce, to our knowledge, of its contribution to eye disease, likely through a gain-of-function mechanism

198 onsequence, degeneration of retinal cells in eye diseases linked to inflammation and inherited blindn

199 Age-related eye disease may be associated with cognitive decline, bu

200 ion screening for refractive error and early eye disease may reduce or prevent a high proportion of i

201 n screening for refractive error and related eye diseases may prevent a high proportion of preschool

202 eration and germinal center formation in dry eye disease mice, suggesting that a stable Ag-dependent

203 otoxic effect and showed improvements on dry eye disease models by stabilizing the tear film, scaveng

204 ly reveals new features of even well-studied eye disease mouse models, such as the oxygen-induced ret

205 is therefore critical to improve imaging of eye disease mouse models.

206 a multitude of more severe symptoms such as eye disease, neonatal infection, and, in rare cases, enc

207 serving as controls or patients with thyroid eye disease, nonspecific orbital inflammation, or granul

208 to abrogate the severe exacerbations of dry eye disease observed in aged mice.

209 Inherited optic neuropathies are rare eye diseases of optic nerve dysfunction that present in

210 acuity in a number of previously untreatable eye diseases, of which the main are age-related macular

211 HZO recurrence was defined as any recurrent eye disease or rash 90 days or more after quiescence of

212 5-year recurrence rates for either recurrent eye disease or rash were 8%, 17%, and 25%, respectively.

213 Graves orbitopathy, also known as thyroid eye disease or thyroid-associated orbitopathy, is visual

214 acles or contact lenses, history of allergic eye disease, or pregnancy.

215 ions of choroidal vessel disease to diabetic eye disease pathogenesis, prognosis, and treatment respo

216 arity measurement could not discriminate dry eye disease pathological scores.

217 and applied to the Prevent Blindness America eye disease prevalence values.

218 Acanthamoeba keratitis, a rare eye disease primarily affecting contact lens wearers, is

219 Immune-driven dry eye disease primarily affects women; the cause for this

220 Despite treatment advances, diabetic eye disease remains a leading cause of visual acuity (VA

221 However, the role of PMNs in dry eye disease remains unexplored.

222 opathy (DR) in the Singapore Epidemiology of Eye Diseases (SEED) Study.

223 years or younger and 108 individuals without eye disease serving as controls.

224 clinical trial to treat currently incurable eye diseases severely affecting cone vision despite reta

225 y corneal inoculation with HSV-1 had reduced eye disease, shedding, and latent infection.

226 e interventional clinical trials in diabetic eye disease since 2017.

227 The Systemic Treatment for Eye Diseases (SITE) Cohort Study suggested long-term saf

228 presence and severity using the Age-Related Eye Disease Study (AREDS) 9-step scale.

229 deep learning in AMD in both the Age-Related Eye Disease Study (AREDS) and AREDS2.

230 a were age over 50, diagnosis of Age-Related Eye Disease Study (AREDS) category 2 and 3, naive neovas

231 hite AREDS2 participants and 145 Age-Related Eye Disease Study (AREDS) participants with DPED.

232 y population and to validate the Age-Related Eye Disease Study (AREDS) simplified severity scale in A

233 macular degeneration (AMD), the Age-Related Eye Disease Study (AREDS) Simplified Severity Scale pred

234 reanalyzed data derived from the Age-Related Eye Disease Study (AREDS), receiving data prepared by th

235 rticipants of the Carotenoids in Age-Related Eye Disease Study (CAREDS) (aged 54 to <75 years) with a

236 The Herpetic Eye Disease Study (HEDS) I showed a significant benefit

237 nd AMD progression data from the Age-Related Eye Disease Study 1 were used to simulate the long-term

238 Using the Age-Related Eye Disease Study 2 (AREDS2) grading system and multimod

239 of peripheral retinal changes in Age-Related Eye Disease Study 2 (AREDS2) participants with at least

240 The Age-Related Eye Disease Study 2 (AREDS2) was a prospective multicent

241 ssociation study (DeePAS) in the Age-Related Eye Disease Study 2 (AREDS2), followed by replication us

242 and/or omega-3 fatty acids, the Age-Related Eye Disease Study 2 (AREDS2), for treatment of AMD and c

243 d randomized clinical trial (the Age-Related Eye Disease Study 2 [AREDS2]), retinal specialists in 82

244 Age-Related Eye Disease Study 2 Ancillary SD OCT study participants

245 nd visual outcomes data from the Age-Related Eye Disease Study 2 Home Monitoring of the Eye study, tr

246 red to be step 1 (normal) on the Age-Related Eye Disease Study 9-step AMD classification system based

247 is and staging, according to the Age-Related Eye Disease Study classification scheme.

248 he National Institutes of Health Age-related Eye Disease Study data set was evaluated.

249 agreement with the gold standard Age-related Eye Disease Study data set.

250 alized Reading Center, using the Age-Related Eye Disease Study grading system.

251 of participants at step 1 on the Age-Related Eye Disease Study scale, considered healthy, were review

252 aphs were assessed by the 9-step Age-Related Eye Disease Study scale.

253 ntation in one or both eyes, and Age-Related Eye Disease Study simplified score), (3) a summary genet

254 alized Reading Center, using the Age-Related Eye Disease Study-2 grading system.

255 hnicities from the Singapore Epidemiology of Eye Disease study.

256 lar to the incidence reported by the Chennai Eye Disease Study.

257 We aimed to validate the Age-Related Eye Diseases Study (AREDS) simplified severity scale of

258 The Singapore Epidemiology of Eye Diseases Study is a population-based trial in which

259 ticipants from the Singapore Epidemiology of Eye Diseases Study were examined between 2004 and 2011.

260 oc analysis of the Singapore Epidemiology of Eye Diseases study, a population-based study of 10033 pa

261 oc analysis of the Singapore Epidemiology of Eye Diseases study, a population-based study of particip

262 diabetes from the Singapore Epidemiology of Eye Diseases Study, of whom 547 (35.8%) had DR.

263 rs and, in turn, preventing key signs of dry eye disease such as aqueous tear secretion, conjunctival

264 hat pathology of age-associated degenerative eye diseases such as adult macular degeneration (AMD), g

265 emming from leaky blood vessels is common in eye diseases such as age-related macular degeneration an

266 properties of tissues to the development of eye diseases such as keratoconus, a disease in which the

267 Ocular neovascularisation underlies blinding eye diseases such as retinopathy of prematurity, prolife

268 lar photoreceptors cause vision loss in many eye diseases, such as age-related macular degeneration a

269 Photoreceptors are damaged in many common eye diseases, such as macular degeneration, retinal deta

270 population ages, more people are affected by eye diseases, such as retinopathies.

271 eases derived from a predefined hierarchical eye disease taxonomy was designed.

272 Clinical diagnoses included thyroid eye disease (TED) (41 scans, 31 patients), non-specific

273 Thyroid eye disease (TED) affects 25-50% of patients with Graves

274 Thyroid eye disease (TED) has been found to reduce quality of li

275 Thyroid eye disease (TED) is a degenerative disease that manifes

276 ween patients with acute and chronic thyroid eye disease (TED).

277 Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes wi

278 or ocular infections, wound healing, and dry-eye disease that affect the vision of millions worldwide

279 abetic retinopathy is a potentially blinding eye disease that threatens the vision of one-ninth of pa

280 optic neuropathies, the most common form of eye diseases that cause irreversible blindness.

281 In a model of dry eye disease, the expression of TRPV1 in TRPM8(+) cold-se

282 ith diabetes have sight-threatening diabetic eye disease, the IRIS algorithm positive predictive valu

283 ivariate analysis found visually significant eye disease to be associated (P < .001; receiver operati

284 Genome-wide Association Studies (GWASs) for eye diseases/traits have delivered a number of novel fin

285 Median age at onset of eye disease was 60 months and duration of eye disease at

286 Dry eye disease was defined from the validated Short Questio

287 A diagnosis of diabetic eye disease was determined by using ICD-9 codes.

288 High incidence of mild to moderate dry eye disease was observed in both groups 1 month postoper

289 Complete evaluation of dry eye disease was performed at 1 and 6 months postoperativ

290 ng a preclinical model of IL-17-mediated dry eye disease, we demonstrate that upon encountering both

291 Longer duration of diabetes and history of eye disease were identified as positive factors for good

292 nces in visual outcome or recurrent herpetic eye disease were identified between the steroid and plac

293 even eligible patients with a history of dry eye disease were randomized 1:1:1:1 to 1 of 4 treatment

294 The most prevalent eye diseases were refractive error (63.2%), conjunctivit

295 t, glaucoma, significant cataract, and major eye diseases, were selected from the population-based Si

296 ated Macular Degeneration (AMD) is a complex eye disease, which is genetically associated with differ

297 ding the epidemiologic factors of infectious eye diseases, which could better inform eye health care

298 large goiters or moderate to severe thyroid eye disease who cannot be treated using antithyroid drug

299 e: To assess the association of VI and major eye diseases with mobility and independence (M&I) in a C

300 onjunctivitis (AHC) is a painful, contagious eye disease, with millions of cases in the last decades.